Contact FDI Site Map Legal and Privacy Information
Healthcare Professionals
Physician Certification
Analytical Performance
Literature
FAQ
MESOMARK Assay Testing Site
References

Patients & Family

Li Z-Q, Verch T, Allard WJ. MESOMARK® in vitro diagnostic test for mesothelioma. Expert Opin Med Diagn. 2007;1(1):137-142.

Scherpereel A, Grigoriu B. Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006;173(10):  1155-1160. 

Scherpereel et al, tested a group of 137 patients, in which 74 had malignant pleural mesothelioma (MPM), 35 suffered from pleural metastasis of carcinomas and 28 were diagnosed with benign pleural lesions from hospitals throughout the northern and western regions of France. The MESOMARK assay (SMRP levels) was used to evaluate serum samples available from this group of patients. The results show a difference in SMRP levels among the three groups, in which the level of SMRP present in patients with MPM was significantly elevated, compared to other evaluated patients. This group concludes that a biomarker to help monitor disease will be a useful tool for physicians. The results of this study clearly show that SMRP values are raised significantly in patients diagnosed with MPM.      

Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612-1616.

This publication investigated the serum concentrations of MESOMARK (SMRP) in a group of patients diagnosed with mesothelioma, diagnosed with other cancers, presenting with pleural fluid not related to mesothelioma, diagnosed with lung inflammatory disease and healthy controls. Results showed that patients diagnosed with mesothelioma had increased concentrations of SMRP than patients who were asbestos exposed and the non-asbestos exposed controls. This research also correlated tumor mass with SMRP concentration, in which the concentrations of SMRP are elevated in patients with the largest tumor mass.  This paper proposes that the use of the SMRP serum value could be useful as an aid in the monitoring of tumor growth. 

Beyer H, Geschwindt R, et al. MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma. Presented at the 19th International Congress of Clinical Chemistry and IFCC/AACC July 24-28, 2005; Orlando, FL.  Click here to download the abstract.

Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93:136-140.

Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447-453.

Hellstrom I, J. Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006;15(5):1014-1020.

Pass HI, Wolaniuk D, et al. Soluble Mesothelioma related peptides : A potential biomarker for malignant pleural mesothelioma. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17,2005; Orlando. FL. 

Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):  397-408.

Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein—a blood test for mesothelioma. Lung Cancer. 2005;49(Suppl 1):S109-111.

Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinomaProc Natl Acad Sci USA. 1999;96(20):11531-11536.